Gilead Sciences appoints Dietmar Berger as Chief Medical Officer
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
The trademark rights for these brands will be transferred to Lupin by March next year.
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
Subscribe To Our Newsletter & Stay Updated